J Am Pharm Assoc (2003). 2021 Sep-Oct;61(5):e78-e83. doi: 10.1016/j.japh.2021.05.002. Epub 2021 May 21.
Postoperative pain management solely with opioids elevates the risk of opioid-related adverse events during hospitalization and after discharge from the hospital. Clinical trials have demonstrated gabapentinoids as viable adjunctive treatments for spinal surgeries. However, only a few practice-based studies have examined the efficacy of gabapentin as an opioid-sparing agent for patients undergoing lumbar laminectomy in rural hospital settings.
To determine the effects of gabapentin on opioid consumption and pain perception in patients who underwent lumbar laminectomy at a rural community hospital.
Data were collected by retrospective chart reviews of 99 patients who underwent lumbar laminectomy at Yavapai Regional Medical Center from January 1, 2017, to July 1, 2019. The patients were stratified into 2 groups: those who were taking gabapentin as outpatients before surgery and were continued on the same dose postoperatively (n = 50, gabapentin group) and those who were not taking gabapentin preoperatively or postoperatively (n = 49, usual-treatment group). The primary end points were opioid consumption in morphine milligram equivalents (MME) and pain for 24 hours postsurgery.
Outcomes from the mixed-model analysis of variance showed significant main effects of group and time for opioid consumption in MME (F = 4.3, P < 0.05 and F = 133.9, P < 0.001, respectively) and numerical pain scale scores (F = 4.0, P < 0.05 and F = 21.4, P < 0.001, respectively) and group-time interaction for opioid consumption in MME (F = 2.6, P = 0.05). Post hoc analyses showed that opioid consumption in MME was significantly lower in the gabapentin group than in the usual-treatment group for the first 6 hours postoperatively. The pain scores were significantly lower in the gabapentin group than in the usual-treatment group across all time periods.
Patients on gabapentin showed reductions in pain perception and postoperative opioid consumption. The results extend the findings from randomized trials to a real-world clinical setting. These data support using gabapentin in conjunction with opioids for pain management of patients undergoing lumbar laminectomy.
单纯使用阿片类药物进行术后疼痛管理会增加患者在住院期间和出院后发生阿片类药物相关不良反应的风险。临床试验已经证实加巴喷丁类药物是脊柱手术的可行辅助治疗药物。然而,只有少数基于实践的研究调查了加巴喷丁作为农村医院环境下腰椎板切除术患者的阿片类药物节约剂的疗效。
确定加巴喷丁对农村社区医院行腰椎板切除术患者的阿片类药物使用和疼痛感知的影响。
对 2017 年 1 月 1 日至 2019 年 7 月 1 日在亚瓦派区域医疗中心接受腰椎板切除术的 99 名患者的病历进行回顾性图表审查,收集数据。患者分为两组:一组为术前在门诊服用加巴喷丁且术后继续服用相同剂量的患者(n=50,加巴喷丁组),另一组为术前和术后均未服用加巴喷丁的患者(n=49,常规治疗组)。主要终点是术后 24 小时内的吗啡等效用量(MME)和疼痛的阿片类药物消耗量。
混合模型方差分析的结果显示,阿片类药物使用的 MME(F=4.3,P<0.05 和 F=133.9,P<0.001)和数字疼痛量表评分(F=4.0,P<0.05 和 F=21.4,P<0.001)均存在显著的组间和时间主效应,且 MME 中的阿片类药物使用存在组间-时间交互作用(F=2.6,P=0.05)。事后分析显示,术后 6 小时内,加巴喷丁组的 MME 阿片类药物使用量明显低于常规治疗组。加巴喷丁组在所有时间段的疼痛评分均明显低于常规治疗组。
使用加巴喷丁的患者疼痛感知和术后阿片类药物使用量均有所降低。该结果将随机试验的结果扩展到真实临床环境中。这些数据支持在接受腰椎板切除术的患者中联合使用阿片类药物和加巴喷丁进行疼痛管理。